Bimatoprost / working resource
Primary source desk
Keep the original documents and the limits of their conclusions within reach.
Start with the product-specific question
What the label says it is for
Bimatoprost for short or sparse eyelashes, with the evidence and its limits in plain view. What should I know about what the label says bimatoprost is for?
Open the Bimatoprost library ↗In a 2012 randomized trial, subjects were randomized over 5 months to once-daily bimatoprost 0.03% (n = 137) or vehicle (n = 141). A higher percentage of subjects treated with bimatoprost 0.03% (78.1%) than vehicle (18.4%) demonstrated at least a 1-grade increase in global eyelash assessment score at week 16 (P < .0001). The abstract lists the short-term duration of the trial and that black subjects were not enrolled secondary to technical requirements of digital image analysis as limitations.
Read the original record ↗
The original record comes first.
These are starting points for the Bimatoprost library. Read the source's exact question, product, population and date. A source can be authoritative for one claim and irrelevant to another.
FDA: human drug compounding ↗
Keep claims and sources together.
In a 2012 randomized trial, subjects were randomized over 5 months to once-daily bimatoprost 0.03% (n = 137) or vehicle (n = 141). A higher percentage of subjects treated with bimatoprost 0.03% (78.1%) than vehicle (18.4%) demonstrated at least a 1-grade increase in global eyelash assessment score at week 16 (P < .0001). The abstract lists the short-term duration of the trial and that black subjects were not enrolled secondary to technical requirements of digital image analysis as limitations.
Supporting record ↗A 2015 randomized controlled trial in patients with idiopathic hypotrichosis reports that treatment effects were maintained for approximately 2 months but markedly diminished 4-6 months following treatment cessation.
Supporting record ↗A pooled safety analysis of six randomized trials reports that most adverse events occurred early in treatment, were mild in intensity, localized to treatment site, and reversible with treatment cessation, and that discontinuations due to adverse events were low (3.2% for bimatoprost and 2.4% for vehicle).
Supporting record ↗A literature review published in Dermatologic Surgery (2021) states that the literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. It concludes that clinical trials may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy, and that the risk of increased iris pigmentation remains inadequately investigated.
Supporting record ↗An observational retrospective chart review of bimatoprost 0.03% found that 27.4% of patients spontaneously recalled experiencing adverse events while on treatment, only 4 adverse events were documented in patient charts, no instances of iris hyperpigmentation occurred, and no serious or severe adverse events were noted. Its author affiliations include Allergan, Inc.
Supporting record ↗The FDA says compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed.
Supporting record ↗These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.